HROW Harrow, Inc. - Common Stock
NASDAQ · Pharmaceuticals · Visualizza su SEC EDGAR ↗ chiudi Ott 2, 2026 10-K/10-Q Ago 10, 2026HROW Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
HROW Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
| Data ex-dividendo | Split | Tipo |
|---|---|---|
| 08 Febbraio 2013 | 1-for-5 | Inverso |
| 24 Febbraio 2012 | 1-for-8 | Inverso |
Informazioni su Harrow, Inc. - Common Stock Panoramica della società da Wikipedia
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary.
Administration and drug pricing advocacy
The company's founder and chief executive officer is Mark L. Baum, a lawyer by training. Baum has been working in the HIV-related pharmacy field since 1999. Baum has been an advocate for drug pricing and patient advocacy, debating former US congressman James Greenwood on this issue at the Oxford Union debating society. In 2016, Baum authored a monograph on drug pricing and has written about pharmaceutical market monopolies in The Wall Street Journal.
Harrow, through its ImprimisRx subsidiary, has sought to create competition for drugs that companies have monopolies through regulatory or other means by marketing new formulations as a compounding pharmacy. This strategy would allow patient access to certain lower cost medication provided, among other conditions, a patient's physician believed such a formulation was best suited for a patient's needs.
In 2015, the company gained international attention when it compounded a pyrimethamine and leucovorin combination formulation which it argued may offer a low-cost, US$1 per pill, "alternative" to Daraprim, a medication which gained public attention after its price in the United States was increased by over 5,000 percent by Martin Shkreli and Turing Pharmaceuticals. In December 2015, Express Scripts accepted the company's product into its formulary.
In 2016, it introduced a lower cost version of tiopronin, and was said to have been working on a version of Mylan's EpiPen. The EpiPen competitor's price target was US$100 for a pair of injectors.
In October 2015, Anthony Principi, a former United States Secretary of Veterans Affairs, was elected to the company's board of directors.
ImprimisRx compounding business
Through its compounding subsidiary ImprimisRx, the company was the first pharmaceutical compounding company to make cGMP ophthalmic eye drops and other sterile compounded products available at a national scale through its FDA-registered outsourcing facility.
ImprimisRx's primary business is that of compounding drugs; that is, combining or altering the formulation of existing drugs to market them to specific populations. As of 2015, the company's business model was driven by development and sale of inexpensive alternatives to off-patent medicines where there was previously only a single manufacturer who could therefore charge outsize prices.
In August 2020, ImprimisRx announced that it was expanding its business beyond compounded drugs and that through a partnership with EyePoint Pharmaceuticals, it would begin to sell Dexycu, an FDA-approved steroid product.
As of 2020, Imprimis operated two pharmaceutical production and distribution facilities, both of which are located in Ledgewood, New Jersey. The company has licenses to operate federally, through the US DEA, and through state pharmacy boards in all 50 of the United States.
Litigation
In 2017, after launching a $49 per month low-cost compounded cyclosporine-A formulation as a potential competitor to Restasis and a glaucoma eye drop program called Simple Drops, the company, alongside Sinceres, became the target of a suit from Allergan for claims connected to supposed false and misleading marketing statements.
The company responded, calling Allergan a "professional litigant" and stating, "Allergan, one of the most powerful Big Pharma companies in the world, has filed this lawsuit against one of the smallest pharmaceutical companies in the world, to snuff out any competition to its high drug price strategies. Allergan, a true Goliath, is bent on ensuring that Americans continue to pay the highest possible prices for its drugs."
During the lawsuit, it was revealed that Allergan engaged in significant lobbying to FDA, state boards of pharmacy, and other federal and state agencies to complain about ImprimisRx. In December 2017, ImprimisRx received a warning letter from the FDA, relaying the agency's determination that the marketing of some of the company's eye drops contained false or misleading claims about efficacy and risks, allegedly in violation of federal law.
After a jury trial, Harrow (then Imprimis Pharmaceuticals) was ordered to pay $0 for disgorgement of profit and $48,500 for lost profit, despite Allergan having sought $60 million.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | HROW | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/E (TTM) | -31.4media 5 anni ≈-115.6 | ≈-115.6 | · | · | |
| P/S (TTM) | 4.1media 5 anni ≈4.8 | ≈4.8 | · | · | |
| P/B (MRQ) | 75.2media 5 anni ≈18.8 | ≈18.8 | 3.2 | Sopravvalutato | |
| Prezzo / FCF (TTM) | 227.8media 5 anni ≈-53.3 | ≈-53.3 | · | · | |
| Prezzo / Flusso di cassa (TTM) | 182.7media 5 anni ≈79.0 | ≈79.0 | · | · | |
| Prezzo / Valore contabile tangibile (MRQ) | -7.1 | · | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | HROW | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Margine lordo (TTM) | 73.3%media 5 anni ≈73.2% | ≈73.2% | · | · | |
| Margine Operativo (TTM) | -1.00%media 5 anni ≈4.1% | ≈4.1% | 2.2% | Debole | |
| EBITDA Margin (Margine EBITDA) | 11.7%media 5 anni ≈5.2% | ≈5.2% | 2.4% | Debole | |
| Margine ante imposte (TTM) | -12.1%media 5 anni ≈-13.6% | ≈-13.6% | 9.0% | Debole | |
| Margine di Profitto Netto (TTM) | -13.5%media 5 anni ≈-14.0% | ≈-14.0% | 4.5% | Debole | |
| ROA (TTM) | -9.8%media 5 anni ≈-10.2% | ≈-10.2% | -0.40% | Sotto la media | |
| ROE (TTM) | -114.8%media 5 anni ≈-49.8% | ≈-49.8% | -3.7% | Sotto la media | |
| ROIC | 218.6%media 5 anni ≈50.7% | ≈50.7% | 7.9% | Di prim'ordine |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | HROW | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Rapporto corrente (MRQ) | 2.2media 5 anni ≈3.9 | ≈3.9 | 4.0 | Bassa liquidità | |
| Quick Ratio | 1.9media 5 anni ≈2.3 | ≈2.3 | 2.6 | Sotto la media |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
| Metrica | Tendenza 5 anni | HROW | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Revenue YoY (Ricavi YoY) | 36.4%media 5 anni ≈41.4% | ≈41.4% | · | · | |
| Revenue CAGR 3Y (CAGR Ricavi 3Y) | 45.4%media 5 anni ≈41.4% | ≈41.4% | · | · | |
| Revenue CAGR 5Y (CAGR Ricavi 5Y) | 41.0% | · | · | · |
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
| Metrica | Tendenza 5 anni | HROW | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Asset Turnover (Rotazione delle attività) | 0.7media 5 anni ≈0.7 | ≈0.7 | 0.7 | Di prim'ordine | |
| Inventory Turnover (Rotazione delle scorte) | 5.6media 5 anni ≈4.8 | ≈4.8 | 2.1 | Di prim'ordine | |
| Receivables Turnover (Rotazione dei crediti) | 2.4media 5 anni ≈9.6 | ≈9.6 | 5.1 | Debole | |
| Revenue / Employee (Ricavi / Dipendente) | ≈$730.0K | · | · | · |
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Giugno 2026 | Ago 11, 2026 | $-0.46 | $-0.18 | -150.5% |
| 31 Marzo 2026 | Mag 7, 2026 | $-0.74 | $-0.41 | -80.7% |
| 31 Dicembre 2025 | $0.17 | $0.38 | -54.8% | |
| 30 Settembre 2025 | $0.22 | $0.27 | -18.1% | |
| 30 Giugno 2025 | $0.13 | $0.01 | — | |
| 31 Marzo 2025 | $-0.50 | $-0.05 | -970.7% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Cost of Revenue | $68M | $49M | $40M | $25M | $18M | $14M | $17M | $17M | $14M | · | · | · | |
| Gross Profit | $204M | $150M | $91M | $63M | $54M | $34M | $34M | $25M | $13M | $10M | $5M | $567.0K | |
| R&D Expense | $21M | $12M | $7M | $3M | $11M | $2M | $2M | $825.0K | $413.0K | $739.0K | $332.0K | $237.0K | |
| SG&A Expense | $153M | $129M | $83M | $58M | $41M | $31M | $33M | $29M | $25M | $18M | $13M | $8M | |
| Operating Expenses | $174M | $142M | $90M | $61M | $53M | $34M | $39M | $30M | $25M | · | · | · | |
| Operating Income | $31M | $9M | $431.0K | $2M | $2M | $385.0K | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M | |
| Interest Expense | · | · | $21M | $7M | $5M | · | · | · | · | · | · | $3.8K | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | $32.4K | |
| Other Non-op | $47.0K | $-185.0K | $-444.0K | $102.0K | $197.0K | $-73.0K | $630.0K | $103.0K | $-884.0K | $2M | $-1M | $29.0K | |
| Pretax Income | $-1M | $-17M | $-24M | $-14M | $-18M | $-3M | $-117.0K | $15M | $-13M | $-19M | · | · | |
| Income Tax | $4M | $161.0K | $701.0K | $75.0K | $133.0K | $4.0K | $8.0K | · | $-935.0K | $-111.0K | · | $3.0K | |
| Net Income | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| EPS (Basic) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | $-0.69 | $-0.13 | $0.01 | $0.67 | $-0.60 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · | $-0.13 | $0.01 | $0.61 | $-0.60 | · | · | · | |
| Shares (Basic) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | 26,757,451 | 25,895,352 | 25,323,159 | 21,917,570 | 20,027,712 | · | · | · | |
| Shares (Diluted) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | · | 25,895,352 | 26,466,098 | 23,812,045 | 20,027,712 | · | · | · | |
| EBITDA | $32M | $10M | $1M | $3M | $3M | $2M | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $73M | $47M | $74M | $96M | $42M | $4M | $5M | · | $4M | $9M | $3M | $8M | |
| Short-term Investments | · | · | $9M | $6M | $9M | $28M | · | · | · | · | · | · | |
| Receivables | $111M | $116M | $36M | $6M | $4M | $3M | $2M | $2M | $2M | $3M | $840.0K | $81.0K | |
| Inventory | $14M | $11M | $11M | $7M | $4M | $4M | $3M | $2M | $2M | $2M | $1M | $373.0K | |
| Prepaid Expense | $14M | $15M | $10M | $4M | $1M | $2M | $586.0K | $837.0K | $714.0K | $938.0K | $786.0K | $241.0K | |
| Other Current Assets | $2M | $3M | $2M | $118.0K | $92.0K | $190.0K | $105.0K | $125.0K | $124.0K | $106.0K | $119.0K | $35.0K | |
| Current Assets | $212M | $190M | $139M | $118M | $61M | $41M | $36M | $33M | $9M | $15M | $6M | $9M | |
| PP&E (Net) | $3M | $4M | $4M | $3M | $3M | $4M | $5M | $6M | $6M | $7M | $3M | $243.0K | |
| PP&E (Gross) | $15M | $15M | $14M | $13M | $11M | $10M | $11M | $11M | $9M | $9M | $3M | $288.0K | |
| Accum. Depreciation | $12M | $11M | $10M | $9M | $8M | $6M | $5M | $4M | $3M | $1M | $300.0K | $45.0K | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $2M | $2M | $2M | $2M | $332.0K | |
| Intangibles | $175M | $185M | $160M | $24M | $16M | $2M | $2M | $3M | $3M | $3M | $3M | $611.0K | |
| Total Assets | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Accounts Payable | $35M | $39M | $25M | $14M | $6M | $4M | $8M | $6M | $4M | $4M | $3M | $787.0K | |
| Short-term Debt | · | $220M | · | · | · | $4M | $2M | $3M | · | $4M | · | · | |
| Current Liabilities | $96M | $91M | $49M | $19M | $10M | $11M | $12M | $12M | $6M | $10M | $5M | $2M | |
| Capital Leases | $8M | $9M | $7M | $7M | $6M | $7M | $6M | · | $720.0K | $1M | $1.0K | $19.0K | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $936.0K | $1M | · | |
| Total Liabilities | $347M | $320M | $242M | $130M | $87M | $31M | $32M | $25M | $21M | $21M | $16M | $2M | |
| Long-term Debt | $250M | $263M | $247M | $152M | $103M | $20M | · | $23M | $23M | · | · | · | |
| Total Debt | · | · | · | · | · | $3M | $2M | $3M | · | $4M | · | · | |
| Common Stock | $37.0K | $35.0K | $35.0K | $30.0K | $27.0K | $26.0K | $26.0K | $24.0K | $21.0K | $19.0K | $10.0K | $9.0K | |
| Paid-in Capital | $209M | $221M | $205M | $137M | $107M | $105M | $102M | $99M | $91M | $83M | · | · | |
| Retained Earnings | $-157M | $-151M | $-134M | $-109M | $-95M | $-77M | $-74M | $-74M | $-89M | $-77M | $-58M | $-42M | |
| Stockholders' Equity | $52M | $70M | $71M | $28M | $11M | $27M | $28M | $25M | $3M | $6M | $-1M | $8M | |
| Liabilities + Equity | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Shares Outstanding | 37,229,159 | 35,622,214 | 35,168,260 | 29,901,530 | 26,902,763 | 25,749,875 | 25,526,931 | 24,339,610 | 20,623,129 | 18,627,915 | 9,755,678 | 9,258,231 |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $1M | $1M | $255.0K | $37.0K | |
| Stock-based Comp | $13M | $18M | $16M | $8M | $6M | $3M | $2M | $2M | $3M | $4M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | $0 | $-935.0K | $-111.0K | · | · | |
| Amort. of Intangibles | $17M | $12M | $10M | $2M | $161.0K | $167.0K | $209.0K | $235.0K | $364.0K | $351.0K | $355.0K | $48.0K | |
| Other Non-cash | $35M | $-24M | $12M | $7M | $16M | $-2M | · | · | · | · | · | · | |
| Operating Cash Flow | $44M | $-22M | $4M | $2M | $5M | $-1M | $950.0K | $687.0K | $-9M | $-11M | $-11M | $-7M | |
| CapEx | $887.0K | $2M | $1M | $3M | $2M | $862.0K | $1M | $2M | $772.0K | $7M | $-995.0K | $174.0K | |
| Investing Cash Flow | $-5M | $-33M | $-153M | $-2M | $-19M | $-981.0K | $-2M | $-2M | $-961.0K | $-7M | $-5M | $-910.0K | |
| Stock Issued | · | · | $65M | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $-13.0K | |
| Net Stock Activity | · | · | · | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | $-13.1K | |
| Financing Cash Flow | $-13M | $29M | $127M | $54M | $51M | $1M | $-1M | $4M | $5M | $25M | $11M | $599.0K | |
| Net Change in Cash | $26M | $-27M | $-22M | $54M | $38M | $-648.0K | $-2M | $3M | $-5M | $6M | $-6M | $-7M | |
| Taxes Paid | $93.0K | $374.0K | · | $75.0K | $11.0K | $4.0K | $17.0K | $4.0K | $9.0K | $9.0K | $1.0K | $1.0K | |
| Free Cash Flow | $43M | $-24M | $2M | $-892.0K | $3M | $-2M | $-518.0K | $-1M | $-10M | $-4M | $-12M | $-7M | |
| Levered FCF | · | · | $-20M | $-8M | · | · | · | · | · | · | · | · |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% | 70.4% | 67.3% | 60.1% | 49.6% | 50.7% | 46.4% | 34.2% | |
| Operating Margin | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% | 0.79% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| Net Margin | -1.9% | -8.8% | -18.8% | -15.9% | -24.9% | -6.9% | 0.33% | 35.4% | -44.8% | -95.7% | -163.6% | -609.4% | |
| Pretax Margin | -0.50% | -8.7% | -18.2% | -15.8% | -24.7% | -7.0% | -0.24% | 35.4% | -48.3% | · | · | · | |
| EBITDA Margin | 11.7% | 5.1% | 1.1% | 3.6% | 4.4% | 4.6% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| ROA | -1.3% | -5.0% | -10.4% | -11.0% | -23.1% | -5.8% | 0.31% | 39.9% | -46.9% | -92.3% | -130.5% | -77.8% | |
| ROE | -8.4% | -24.9% | -49.6% | -72.5% | -93.6% | -12.2% | 0.64% | 117.8% | -265.0% | -756.4% | -470.0% | -87.0% | |
| ROIC | 218.6% | 12.8% | 0.63% | 7.0% | 14.4% | 1.3% | · | · | -431.5% | · | · | · |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 | 3.7 | 3.0 | 2.8 | 1.5 | 1.5 | 1.1 | 5.8 | |
| Quick Ratio | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 | 0.6 | 0.2 | 0.2 | 1.0 | 1.2 | 0.7 | 5.3 | |
| Debt / Equity | · | · | · | · | · | 0.1 | 0.1 | 0.1 | · | 0.6 | · | · | |
| Interest Coverage | · | · | 0.0 | 0.3 | · | · | · | · | · | · | · | -2670.2 |
Efficienza
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.6 | 0.6 | 0.7 | 0.9 | 0.8 | 0.9 | 1.1 | 1.0 | 1.0 | 0.8 | 0.1 | |
| Inventory Turnover | 5.6 | 4.6 | 4.6 | 4.7 | 4.5 | 4.0 | 6.5 | 8.1 | · | · | · | · | |
| Receivables Turnover | 2.4 | 2.6 | 6.1 | 16.5 | 20.3 | 20.9 | 26.1 | 24.0 | 12.0 | 10.6 | 21.1 | 40.8 |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.41 | $1.96 | $2.01 | $0.92 | $0.42 | $1.06 | $1.09 | $1.02 | $0.13 | $0.35 | $-0.14 | $0.88 | |
| Revenue / Share | $7.41 | $5.60 | $3.99 | · | · | $1.89 | $1.93 | $1.74 | · | · | · | · | |
| Cash Flow / Share | $1.19 | $-0.62 | $0.12 | · | · | $-0.04 | $0.04 | $0.03 | · | · | · | · | |
| Cash / Share | $1.96 | $1.33 | $2.11 | · | $1.57 | $0.16 | · | · | $0.19 | $0.48 | $0.28 | $0.89 | |
| EPS (TTM) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · | $-0.13 | $0.01 | $0.61 | $-0.60 | · | · | · |
Tassi di Crescita
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 36.4% | 53.3% | 46.9% | 22.2% | 48.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 45.4% | 40.2% | 38.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 41.0% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Net Income TTM | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| Market Cap | $1.82B | $1.20B | $394M | $441M | $232M | $177M | $199M | $138M | $35M | $47M | $68M | $69M | |
| Enterprise Value | · | · | · | · | · | $175M | · | · | · | $42M | · | · | |
| P/E | -350.0 | -68.5 | -14.9 | -28.9 | · | -52.8 | 778.0 | 9.3 | -2.8 | · | · | · | |
| P/S | 6.7 | 6.0 | 3.0 | 5.0 | 3.2 | 3.6 | 3.9 | 3.3 | 1.3 | 2.3 | 7.0 | 41.8 | |
| P/B | 34.8 | 17.2 | 5.6 | 16.0 | 20.6 | 6.5 | 7.2 | 5.6 | 13.4 | 7.2 | -48.8 | 8.5 | |
| P / Tangible Book | · | · | · | 124.7 | · | 7.1 | · | · | · | · | · | · | |
| P / Cash Flow | 41.6 | -53.8 | 102.6 | 258.9 | 45.7 | -160.6 | 209.1 | 201.6 | -4.0 | -4.2 | -6.1 | -9.8 | |
| P / FCF | 42.4 | -50.2 | 165.5 | -494.8 | 70.5 | -90.0 | -383.4 | -128.1 | -3.7 | -10.8 | -5.6 | -9.6 | |
| EV / EBITDA | · | · | · | · | · | 77.3 | · | · | · | -2.6 | · | · | |
| EV / FCF | · | · | · | · | · | -89.3 | · | · | · | -9.6 | · | · | |
| EV / Revenue | · | · | · | · | · | 3.6 | · | · | · | 2.1 | · | · | |
| Earnings Yield | -0.29% | -1.5% | -6.7% | -3.5% | · | -1.9% | 0.13% | 10.7% | -35.3% | · | · | · |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71M | $44M | $89M | $72M | $64M | $48M | $67M | $49M | $49M | $35M | $36M | $34M | $33M | $26M | $20M | $23M | |
| Cost of Revenue | $20M | $17M | $18M | $18M | $16M | $16M | $14M | $12M | $13M | $11M | $11M | $10M | $10M | $8M | $6M | $7M | |
| Gross Profit | $50M | $27M | $71M | $54M | $48M | $32M | $53M | $37M | $36M | $24M | $25M | $24M | $23M | $18M | $14M | $16M | |
| R&D Expense | $8M | $6M | $12M | $3M | $3M | $3M | $5M | $2M | $3M | $2M | $3M | $1M | $1M | $734.0K | $703.0K | $775.0K | |
| SG&A Expense | $53M | $43M | $43M | $36M | $33M | $41M | $35M | $34M | $32M | $29M | $26M | $21M | $20M | $16M | $15M | $15M | |
| Operating Expenses | $61M | $49M | $55M | $39M | $36M | $44M | $40M | $36M | $35M | $31M | $30M | $22M | $21M | $17M | $16M | $16M | |
| Operating Income | $-11M | $-22M | $16M | $15M | $11M | $-11M | $13M | $1M | $2M | $-7M | $-5M | $2M | $2M | $1M | $-2M | $-94.0K | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $5M | · | $6M | $6M | $5M | $2M | $2M | |
| Other Non-op | $0 | · | $7M | $61.0K | $-6.0K | $-7M | $6M | $4.0K | $46.0K | $-7M | $-100.0K | $-195.0K | $-178.0K | $29.0K | · | · | |
| Pretax Income | $-17M | $-28M | $10M | $1M | $5M | $-18M | $6M | $-4M | $-6M | $-14M | $-10M | $-3M | $-4M | $-7M | $1M | $-6M | |
| Income Tax | $0 | $25.0K | · | · | $0 | · | $-514.0K | $20.0K | $655.0K | · | $-535.0K | $2M | $-15.0K | $-288.0K | $0 | $35.0K | |
| Net Income | $-17M | $-28M | $7M | $1M | $5M | $-18M | $7M | $-4M | $-6M | $-14M | $-9M | $-4M | $-4M | $-7M | $1M | $-6M | |
| EPS (Basic) | $-0.46 | $-0.74 | $0.19 | $0.03 | $0.14 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| EPS (Diluted) | $-0.46 | $-0.74 | $0.20 | $0.03 | $0.13 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| Shares (Basic) | 37,350,401 | 37,231,321 | · | 37,145,440 | 36,790,306 | 35,826,452 | · | 35,702,200 | 35,618,977 | 35,469,638 | · | 34,255,197 | 30,458,677 | 30,289,730 | · | 27,349,642 | |
| Shares (Diluted) | 37,350,401 | 37,231,321 | · | 38,875,005 | 38,853,855 | 35,826,452 | · | 35,702,200 | 35,618,977 | 35,469,638 | · | 34,255,197 | 30,458,677 | 30,289,730 | · | 27,349,642 | |
| EBITDA | $-11M | $-22M | · | $15M | $12M | $-11M | · | $1M | $2M | $-7M | · | $2M | $2M | $1M | · | $-94.0K |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $84M | $95M | $73M | $74M | $53M | $67M | $47M | $73M | $71M | $69M | · | $66M | · | · | $96M | $45M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | $7M | · | $8M | $7M | $8M | $6M | $4M | |
| Receivables | $119M | $101M | $111M | $78M | $79M | $77M | $116M | $54M | $52M | $29M | · | $18M | $18M | $12M | $6M | $7M | |
| Inventory | $17M | $16M | $14M | $13M | $12M | $11M | $11M | $10M | $9M | $11M | · | $9M | $9M | $9M | $7M | $5M | |
| Prepaid Expense | $10M | $14M | $14M | $13M | $12M | $15M | $15M | $11M | $7M | $10M | · | $9M | $4M | $4M | $4M | $3M | |
| Other Current Assets | $1M | $1M | $2M | $3M | $3M | $3M | $3M | $1M | $1M | $2M | · | $118.0K | $427.0K | $118.0K | $118.0K | $73.0K | |
| Current Assets | $229M | $226M | $212M | $178M | $155M | $170M | $190M | $147M | $139M | $125M | · | $110M | $60M | $52M | $118M | $64M | |
| PP&E (Net) | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $3M | $3M | · | $4M | $4M | $4M | $3M | $3M | |
| PP&E (Gross) | · | · | $15M | $15M | $15M | $15M | $15M | $15M | $14M | $14M | · | $13M | $13M | $13M | $13M | $12M | |
| Accum. Depreciation | · | · | $12M | $12M | $12M | $11M | $11M | $11M | $11M | $10M | · | $10M | $10M | $9M | $9M | $9M | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | · | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | |
| Intangibles | $176M | $181M | $175M | $172M | $177M | $181M | $185M | $189M | $155M | $157M | · | $163M | $150M | $152M | $24M | $20M | |
| Total Assets | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Accounts Payable | $26M | $26M | $35M | $19M | $23M | $37M | $39M | $25M | $22M | $15M | · | $13M | $18M | $14M | $14M | $14M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $59.0K | · | · | · | · | |
| Short-term Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $102M | $91M | $96M | $65M | $249M | $187M | $91M | $95M | $54M | $42M | · | $19M | $23M | $18M | $19M | $18M | |
| Capital Leases | $7M | $8M | $8M | $8M | $8M | $9M | $9M | $10M | $7M | $7M | · | $7M | $7M | $7M | $7M | $8M | |
| Total Liabilities | $402M | $391M | $347M | $316M | $296M | $308M | $320M | $294M | $248M | $235M | · | $211M | $202M | $196M | $130M | $98M | |
| Long-term Debt | · | $300M | $250M | $347M | $251M | $257M | · | $231M | $236M | $243M | · | $252M | $240M | $244M | · | $98M | |
| Total Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $37.0K | $37.0K | $37.0K | $37.0K | $36.0K | $35.0K | $35.0K | $35.0K | $35.0K | $35.0K | · | $35.0K | $30.0K | $30.0K | $30.0K | $27.0K | |
| Paid-in Capital | $217M | $213M | $209M | $210M | $214M | $226M | $221M | $216M | $212M | $208M | · | $200M | $143M | $138M | $137M | $112M | |
| Retained Earnings | $-201M | $-184M | $-157M | $-163M | $-164M | $-169M | $-151M | $-158M | $-154M | $-147M | · | $-125M | $-120M | $-116M | $-109M | $-111M | |
| Stockholders' Equity | $15M | $29M | $52M | $47M | $50M | $56M | $70M | $58M | $59M | $61M | · | $76M | $22M | $22M | $28M | $1M | |
| Liabilities + Equity | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Shares Outstanding | 37,484,233 | 37,269,400 | 37,229,159 | 37,034,582 | 36,714,679 | 35,654,171 | 35,622,214 | 35,611,365 | 35,479,492 | 35,380,955 | · | 35,117,621 | 30,276,938 | 30,056,370 | 29,901,530 | 27,074,307 |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $460.0K | $455.0K | $330.0K | $326.0K | $347.0K | $312.0K | $321.0K | $351.0K | $301.0K | $296.0K | $435.0K | $405.0K | $398.0K | $225.0K | $387.0K | $247.0K | |
| Stock-based Comp | $4M | $4M | $4M | $3M | $875.0K | $5M | $5M | $4M | $4M | $4M | $4M | $4M | $5M | $2M | $2M | $2M | |
| Deferred Tax | · | · | · | · | · | · | · | $20.0K | · | · | · | · | $0 | $-288.0K | · | · | |
| Amort. of Intangibles | $6M | $5M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $3M | $2M | $378.0K | $398.0K | |
| Other Non-cash | · | · | · | · | · | $33M | · | · | · | $4M | · | · | · | · | · | · | |
| Operating Cash Flow | $-10M | $-9M | $8M | $17M | $-803.0K | $20M | $-18M | $3M | $-3M | $-5M | $9M | $-1M | $5M | $-8M | $-4M | $-410.0K | |
| CapEx | $491.0K | $194.0K | $341.0K | $210.0K | $166.0K | $170.0K | $555.0K | $604.0K | $344.0K | $92.0K | $194.0K | $520.0K | $250.0K | $496.0K | $878.0K | $1M | |
| Investing Cash Flow | $-534.0K | $-18M | $-5M | $-225.0K | $-293.0K | $-212.0K | $-38M | $-597.0K | $5M | $-110.0K | $-203.0K | $-20M | $-1M | $-131M | $-5.0K | $-1M | |
| Financing Cash Flow | $-466.0K | $49M | $-5M | $5M | $-13M | $23.0K | $30M | $-721.0K | $73.0K | $-809.0K | $-18.0K | $64M | $189.0K | $62M | $55M | $0 | |
| Net Change in Cash | $-11M | $22M | $-1M | $21M | $-14M | $19M | $-25M | $2M | $2M | $-6M | $8M | $43M | $4M | $-77M | $51M | $-1M | |
| Taxes Paid | · | · | $55.0K | $0 | $0 | $38.0K | · | · | · | · | · | · | · | · | $0 | $35.0K | |
| Free Cash Flow | · | $-9M | · | · | · | $19M | · | · | · | $-5M | · | · | · | $-9M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-13M | · | · |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.3% | 61.2% | · | 75.3% | 74.5% | 67.5% | · | 75.6% | 74.4% | 69.5% | · | 70.6% | 70.1% | 68.3% | · | 70.5% | |
| Operating Margin | -15.6% | -50.0% | · | 20.6% | 17.9% | -23.5% | · | 2.7% | 3.1% | -20.0% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| Net Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | -37.2% | · | -8.6% | -13.2% | -39.2% | · | -12.8% | -12.6% | -25.4% | · | -28.3% | |
| Pretax Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | · | · | -8.5% | -11.9% | -39.2% | · | -8.3% | -12.7% | -26.6% | · | -28.2% | |
| EBITDA Margin | -15.6% | -50.0% | · | 21.0% | 18.4% | -22.8% | · | 2.7% | 3.1% | -19.2% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| ROA | -4.5% | -7.0% | · | 0.29% | 1.5% | -5.4% | · | -1.3% | -2.4% | -5.3% | · | -2.3% | -2.6% | -4.2% | · | -6.4% | |
| ROE | -53.3% | -64.8% | · | 1.9% | 9.2% | -30.4% | · | -6.3% | -16.0% | -32.9% | · | -11.4% | -30.0% | -41.5% | · | -72.6% | |
| ROIC | -72.4% | -77.0% | · | · | · | · | · | 2.3% | 2.9% | · | · | 3.5% | 10.5% | 5.3% | · | -7.8% |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.5 | · | 2.7 | 0.6 | 0.9 | · | 1.5 | 2.6 | 3.0 | · | 5.8 | 2.6 | 2.9 | · | 3.5 | |
| Quick Ratio | 2.0 | 2.1 | · | 2.3 | 0.5 | 0.8 | · | 1.3 | 2.3 | 2.5 | · | 4.9 | 1.1 | 1.1 | · | 3.0 | |
| Debt / Equity | · | · | · | 5.2 | 3.7 | 1.9 | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.3 | · | 0.3 | 0.4 | 0.3 | · | -0.1 |
Efficienza
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.4 | · | 1.3 | 1.4 | 1.1 | · | 1.4 | 1.5 | 1.2 | · | 1.5 | |
| Receivables Turnover | 0.7 | 0.5 | · | 1.1 | 1.0 | 0.9 | · | 1.4 | 1.4 | 1.7 | · | 2.7 | 2.7 | 2.9 | · | 4.2 |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.41 | $0.77 | · | $1.27 | $1.35 | $1.58 | · | $1.63 | $1.65 | $1.71 | · | $2.16 | $0.74 | $0.73 | · | $0.04 | |
| Revenue / Share | $1.89 | $1.19 | · | $1.84 | $1.64 | $1.34 | · | $1.38 | $1.37 | $0.98 | · | $1.00 | $1.10 | $0.86 | · | · | |
| Cash Flow / Share | · | $-0.24 | · | · | · | $0.55 | · | · | · | $-0.13 | · | · | · | $-0.27 | · | · | |
| Cash / Share | $2.24 | $2.54 | · | $2.01 | $1.44 | $1.87 | · | $2.04 | $2.00 | $1.94 | · | $1.87 | · | · | · | $1.66 | |
| EPS (TTM) | $-0.97 | $-0.38 | · | $-0.15 | $-0.30 | $-0.61 | · | $-0.94 | $-0.95 | $-0.91 | · | $-0.44 | $-0.55 | $-0.64 | · | · |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $276M | $269M | · | $250M | $228M | $213M | · | $169M | $154M | $139M | · | $114M | $103M | $93M | · | $88M | |
| Net Income TTM | $-37M | $-15M | · | $-5M | $-10M | $-22M | · | $-33M | $-34M | $-31M | · | $-14M | $-16M | $-18M | · | $-23M | |
| Market Cap | $1.59B | $1.31B | · | $1.78B | $1.12B | $948M | · | $1.60B | $741M | $468M | · | $505M | $576M | $636M | · | $327M | |
| Enterprise Value | · | · | · | $1.95B | $1.25B | $990M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -43.8 | -92.8 | · | -321.2 | -101.8 | -43.6 | · | -47.8 | -22.0 | -14.5 | · | -32.7 | -34.6 | -33.1 | · | · | |
| P/S | 5.8 | 4.9 | · | 7.1 | 4.9 | 4.5 | · | 9.5 | 4.8 | 3.4 | · | 4.4 | 5.6 | 6.9 | · | 3.7 | |
| P/B | 104.7 | 45.8 | · | 38.0 | 22.6 | 16.8 | · | 27.6 | 12.7 | 7.7 | · | 6.7 | 25.7 | 29.1 | · | 268.5 | |
| P / Cash Flow | · | -146.1 | · | · | · | 48.2 | · | · | · | -101.1 | · | · | · | -77.4 | · | · | |
| EV / Revenue | · | · | · | 7.8 | 5.5 | 4.7 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -2.3% | -1.1% | · | -0.31% | -0.98% | -2.3% | · | -2.1% | -4.5% | -6.9% | · | -3.1% | -2.9% | -3.0% | · | · |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ricavi | $272M | $200M | $130M | $89M | $72M |
| Margine Lordo % | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% |
| Margine Operativo % | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% |
| Utile netto | $-5M | $-17M | $-24M | $-14M | $-18M |
| EPS Diluito | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Rapporto corrente | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 |
| Quick Ratio | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flusso di cassa libero | $43M | $-24M | $2M | $-892.0K | $3M |
Proprietari istituzionali (13F) 242 filer · $1.1B totale · Aggiornato al 30 Settembre 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 41 (-6 vs trimestre precedente) | 34 (+4 vs trimestre precedente) | 80 (+11 vs trimestre precedente) | 69 (-9 vs trimestre precedente) | -305K |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $116.372.768 | 2.740.117 | 10,90% | Azioni |
| Opaleye Management Inc. | $101.928.000 | 2.400.000 | 9,55% | Azioni |
| VANGUARD GROUP INC | $94.162.467 | 1.921.683 | 8,82% | Azioni |
| Private Capital Management, LLC | $67.899.762 | 1.598.770 | 6,36% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $60.188.994 | 1.417.212 | 5,64% | Azioni |
| Deep Track Capital, LP | $41.153.430 | 969.000 | 3,86% | Azioni |
| STATE STREET CORP | $39.917.043 | 939.888 | 3,74% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $38.466.487 | 905.560 | 3,60% | Azioni |
| BAMCO INC /NY/ | $34.373.094 | 809.350 | 3,22% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $31.550.963 | 742.900 | 2,96% | Opzione Call |
| DIMENSIONAL FUND ADVISORS LP | $28.325.286 | 667.036 | 2,65% | Azioni |
| Divisadero Street Capital Management, LP | $18.650.913 | 439.155 | 1,75% | Azioni |
| CITADEL ADVISORS LLC | $16.622.758 | 391.400 | 1,56% | Opzione Call |
| RICE HALL JAMES & ASSOCIATES, LLC | $16.459.036 | 387.545 | 1,54% | Azioni |
| MARSHALL WACE, LLP | $15.689.905 | 369.435 | 1,47% | Azioni |
| CITADEL ADVISORS LLC | $15.283.849 | 359.874 | 1,43% | Azioni |
| NORTHERN TRUST CORP | $13.726.559 | 323.206 | 1,29% | Azioni |
| Schonfeld Strategic Advisors LLC | $13.574.473 | 319.625 | 1,27% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $13.531.367 | 318.610 | 1,27% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $11.623.869 | 273.696 | 1,09% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $9.998.202 | 235.418 | 0,94% | Azioni |
| CITADEL ADVISORS LLC | $9.895.510 | 233.000 | 0,93% | Opzione Put |
| Westside Investment Management, Inc. | $9.515.477 | 224.051 | 0,89% | Azioni |
| FirstWave Capital Management LLC | $9.002.833 | 211.981 | 0,84% | Azioni |
| Blackhawk Capital Partners, LLC | $8.631.645 | 203.241 | 0,81% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $8.074.227 | 190.116 | 0,76% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7.827.221 | 184.300 | 0,73% | Opzione Put |
| JANE STREET GROUP, LLC | $7.772.010 | 183.000 | 0,73% | Opzione Call |
| STIFEL FINANCIAL CORP | $7.682.532 | 180.893 | 0,72% | Azioni |
| GOLDMAN SACHS GROUP INC | $6.573.380 | 154.777 | 0,62% | Azioni |
| ROYCE & ASSOCIATES LP | $6.565.310 | 154.587 | 0,62% | Azioni |
| Crawford Fund Management, LLC | $6.035.836 | 142.120 | 0,57% | Azioni |
| Ikarian Capital, LLC | $5.766.364 | 135.775 | 0,54% | Azioni |
| Advantage Alpha Capital Partners LP | $5.374.624 | 111.553 | 0,50% | Azioni |
| MORGAN STANLEY | $5.105.094 | 120.204 | 0,48% | Azioni |
| Diametric Capital, LP | $4.965.082 | 116.908 | 0,47% | Azioni |
| WOODMONT INVESTMENT COUNSEL LLC | $4.748.571 | 111.810 | 0,44% | Azioni |
| BANK OF AMERICA CORP /DE/ | $4.565.398 | 107.497 | 0,43% | Azioni |
| FIRST TRUST ADVISORS LP | $4.260.378 | 100.315 | 0,40% | Azioni |
| STATE OF WISCONSIN INVESTMENT BOARD | $4.146.219 | 97.627 | 0,39% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $3.934.590 | 92.644 | 0,37% | Azioni |
| 12th Street Asset Management Company, LLC | $3.882.140 | 91.409 | 0,36% | Azioni |
| Lumbard & Kellner, LLC | $3.835.975 | 90.322 | 0,36% | Azioni |
| Steward Partners Investment Advisory, LLC | $3.832.960 | 90.251 | 0,36% | Azioni |
| Bank of New York Mellon Corp | $3.625.366 | 85.363 | 0,34% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $3.575.210 | 84.182 | 0,33% | Azioni |
| EQUITABLE TRUST CO | $3.371.184 | 79.378 | 0,32% | Azioni |
| Squarepoint Ops LLC | $3.126.726 | 73.622 | 0,29% | Azioni |
| DEUTSCHE BANK AG\ | $3.009.509 | 70.862 | 0,28% | Azioni |
| KENNEDY CAPITAL MANAGEMENT LLC | $3.004.668 | 70.748 | 0,28% | Azioni |
Attivisti e proprietari del 5%+ 5 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Mark L. Baum ×3 depositi | 07 Aprile 2025 | 10,69% | Modifica | · | SEC |
| 27 Aprile 2021 | · | Deposito iniziale | · | SEC | |
| Robert J. Kammer, as Trustee of The Robert J. Kammer Living Trust established 6/1/2000, Robert J. Kammer ×2 depositi | 30 Agosto 2016 | · | Deposito iniziale | Investimento passivo | SEC |
| Dr. Robert J. Kammer ×2 depositi | 16 Agosto 2013 | · | Deposito iniziale | · | SEC |
| DermaStar International, LLC ×7 depositi | 10 Agosto 2012 | · | Deposito iniziale | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insider aziendali 32 insider · 10 dirigenti · 17 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Mark L. Baum | CHIEF EXECUTIVE OFFICER | 14 Maggio 2026 P | 2.996.130 | 1 | 0 | $302.000 |
| John P. Saharek | CEO & President, ImprimisRx | 03 Aprile 2025 M | 467.388 | 0 | 0 | $0 |
| Juliet Singh | CEO, Director and President | 18 Giugno 2009 A | 1.954.125 | 0 | 0 | $0 |
| Andrew Boll | PRESIDENT AND CFO | 14 Maggio 2026 P | 814.679 | 1 | 0 | $104.650 |
| Clayton D Edwards | Chief Operating Officer | 13 Aprile 2017 A | · | 0 | 0 | $0 |
| Amir Shojaei | CHIEF SCIENTIFIC OFFICER | 14 Agosto 2026 M | 0 | 0 | 1 | $-450.000 |
| Patrick William Sullivan | CHIEF COMMERCIAL OFFICER | 30 Gennaio 2026 A | · | 0 | 0 | $0 |
| Randall E. Pollard | CHIEF ACCOUNTING OFFICER | 01 Settembre 2025 A | · | 0 | 0 | $0 |
| Joachim Ph Schupp | CHIEF MEDICAL OFFICER | 01 Aprile 2013 A | · | 0 | 0 | $0 |
| Terry Nida | Chief Business Officer | 26 Febbraio 2010 A | · | 0 | 0 | $0 |
| Perry J. Sternberg | Direttore | 18 Giugno 2026 A | · | 0 | 0 | $0 |
| Adrienne L Graves | Direttore | 18 Giugno 2026 A | 1.000 | 1 | 0 | $31.070 |
| Lauren P Silvernail | Direttore | 18 Giugno 2026 A | 1.000 | 1 | 0 | $31.000 |
| Martin A. Makary | Direttore | 14 Giugno 2024 A | 45.000 | 0 | 0 | $0 |
| Teresa Sparks | Direttore | 21 Giugno 2023 A | · | 0 | 0 | $0 |
| Lawrence R. Van Horn | Direttore | 21 Giugno 2023 A | 1.860 | 0 | 0 | $0 |
| Richard L Lindstrom MD | Direttore | 30 Settembre 2022 S | 26.100 | 0 | 0 | $0 |
| Robert J Kammer | Direttore | 25 Giugno 2021 A | 797.327 | 0 | 0 | $0 |
| Anthony Principi | Direttore | 28 Settembre 2020 M | 93.798 | 0 | 0 | $0 |
| Stephen G Austin | Direttore | 16 Marzo 2020 M | 91.987 | 0 | 0 | $0 |
| William H. Nelson | Direttore | 10 Giugno 2016 A | 12.904 | 0 | 0 | $0 |
| August Shelby Bassani | Direttore | 04 Settembre 2014 A | 13.488 | 0 | 0 | $0 |
| Peter C Kenny | Direttore | 02 Ottobre 2013 A | 8.947 | 0 | 0 | $0 |
| Paul Finnegan | Direttore | 27 Giugno 2013 A | 6.865 | 0 | 0 | $0 |
| Jeffrey J Abrams | Direttore | 27 Giugno 2013 A | 45.927 | 0 | 0 | $0 |
| Opaleye Management Inc. | Proprietario del 10% | 04 Marzo 2026 S | 59.428 | 0 | 6 | $-9.183.890 |
| Donald Paul Miloni | Proprietario del 10% | 19 Maggio 2015 S | 468.576 | 0 | 0 | $0 |
| DERMASTAR INTERNATIONAL, LLC | Proprietario del 10% | 12 Luglio 2012 J | 0 | 0 | 0 | $0 |
| John N Bonfiglio | · | 20 Ottobre 2010 A | 50.000 | 0 | 0 | $0 |
| John T Lomoro | · | 19 Giugno 2009 A | · | 0 | 0 | $0 |
| Lynn C Swann | · | 21 Novembre 2008 A | 25.000 | 0 | 0 | $0 |
| Anthony S Thornley | · | 21 Novembre 2008 A | 60.900 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 32 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 1,23% | 6.543 NS | 31 Luglio 2026 | N-PORT |
| IWC · iShares Trust | 0,28% | 110.031 SH | 11 Settembre 2026 | Giornaliero |
| IHE · iShares Trust | 0,28% | 122.556 SH | 11 Settembre 2026 | Giornaliero |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,25% | 82.646 NS | 31 Luglio 2026 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,12% | 41.081 NS | 31 Luglio 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,08% | 34.722 SH | 19 Agosto 2026 | Giornaliero |
| FSMD · FIDELITY COVINGTON TRUST | 0,08% | 50.393 NS | 31 Luglio 2026 | N-PORT |
| IWO · iShares Trust | 0,08% | 302.749 SH | 11 Settembre 2026 | Giornaliero |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,08% | 2.662 SH | 02 Ottobre 2026 | Giornaliero |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 7.488 NS | 31 Luglio 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,04% | 7.406 NS | 31 Luglio 2026 | N-PORT |
| RSSL · Global X Funds | 0,04% | 15.475 NS | 31 Luglio 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,04% | 186.298 SH | 19 Agosto 2026 | Giornaliero |
| IWM · iShares Trust | 0,04% | 826.648 SH | 11 Settembre 2026 | Giornaliero |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 2.979 SH | 02 Ottobre 2026 | Giornaliero |
| ISCG · iShares Trust | 0,03% | 8.739 SH | 11 Settembre 2026 | Giornaliero |
| DFAS · Dimensional ETF Trust | 0,03% | 125.599 NS | 31 Luglio 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 383.679 SH | 19 Agosto 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | 0,02% | 94.953 SH | 19 Agosto 2026 | Giornaliero |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 15.109 NS | 31 Luglio 2026 | N-PORT |
| WSML · iShares Trust | 0,01% | 2.287 SH | 11 Settembre 2026 | Giornaliero |
| DXUV · Dimensional ETF Trust | 0,01% | 949 NS | 31 Luglio 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,01% | 61.585 NS | 31 Luglio 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 10.408 NS | 31 Luglio 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 2.739 NS | 31 Luglio 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 11.363 NS | 31 Luglio 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 45.401 SH | 11 Settembre 2026 | Giornaliero |
| IWV · iShares Trust | 0,00% | 7.042 SH | 04 Settembre 2026 | Giornaliero |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.001.445 SH | 19 Agosto 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.637 SH | 19 Agosto 2026 | Giornaliero |
| ISCB · iShares Trust | · | 1.222 SH | 11 Settembre 2026 | Giornaliero |
| SMLF · iShares Trust | · | 34.093 SH | 11 Settembre 2026 | Giornaliero |
HROW Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
Target Price a 12 Mesi
9 analisti · 2026-09-29Target medio $65.00 +113,3%
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| HROW | $1.82B | -350.0 | 36.4% | -1.9% | -8.4% | 75.0% |
| XERS | $1.30B | · | 43.7% | 0.19% | -19.7% | · |
| KARD | · | · | · | · | · | · |
| OMER | $1.23B | -343.6 | · | · | 1.9% | · |
| AVLN | · | · | · | · | · | · |
| LBRX | $563M | -7.1 | · | · | -25.5% | · |
| YARW | · | · | · | · | · | · |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| PCRX | $1.06B | 161.8 | 3.6% | 0.97% | 0.97% | · |
| SPTX | · | · | · | · | · | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.